RxDoctor Payments Data

Carolyn Castillo, MD

Internal Medicine · Albuquerque, NMNPI 1487764387

Payments from drug & device makers

$347in general payments, 2019–2025

Across 17 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$71
  • Arbor Pharmaceuticals, Inc.$53
  • Boehringer Ingelheim$49
  • Novartis$43
  • United Therapeutics Corporation$28
  • Johnson & Johnson$21
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$347100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$347 in reported general payments places this provider in the 75th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$112,967
Medicare patients
389
Services billed
1,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$96,806
OzempicSemaglutide32$48,974
XareltoRivaroxaban45$48,632
TrulicityDulaglutide27$45,527
JanuviaSitagliptin Phosphate30$43,191
JardianceEmpagliflozin25$35,076
MyrbetriqMirabegron32$29,920
FarxigaDapagliflozin Propanediol15$24,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$22,787
Spiriva HandihalerTiotropium Bromide16$21,291
Levothyroxine Sodium719$11,162
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$10,564
Atorvastatin Calcium719$9,317
Breo ElliptaFluticasone/Vilanterol12$8,404
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$8,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$96,80660 claims
Novo NordiskOzempic$20$48,97432 claims
Johnson & JohnsonXarelto$21$48,63245 claims
Lilly USA, LLCTrulicity$16$45,52727 claims
Boehringer IngelheimJardiance$49$35,07625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →